Michael Matthew Smits

US Patent:

8163796, Apr 24, 2012

Filed:

Jul 20, 2010

Appl. No.:

12/804376

Inventors:

Morris A. Johnson - Greenville WI, US
Michael M. Smits - Appleton WI, US

Assignee:

BioChemical Solutions, LLC - Appleton WI

International Classification:

A01N 43/08
A01N 43/36
A01N 37/08
A61K 31/34
A61K 31/40
A61K 31/215

US Classification:

514472, 514423, 514530

Abstract:

A novel treatment regimen is described for the control and elimination of cancer cell populations including cancer stem cells. The disclosed protocol consists of a pretreatment step followed by a treatment step. The pretreatment step sensitizes cancer cells to apoptosis by altering their intracellular oxidation-reduction state via reduced glutathione depletion. The treatment step involves the sequential administration of a cancerostatic dicarbonyl compound to induce apoptosis. The use of nanoparticle delivery systems further enhances both the pharmacokinetic and pharmacodynamic properties of the pretreatment compounds and the cancerostatic dicarbonyls. Since the pretreatment and treatment compounds are carefully selected and delivered, normal cells are not affected and side effects are kept to a minimum.